Scottish Medicines Consortium daratumumab (Darzalex)

in the absence of a submission from the holder of the marketing authorisation

daratumumab (Darzalex®) is not recommended for use within NHSScotland.

Indication under review: in combination with bortezomib, melphalan and prednisone for the treatment of adult patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant.

The holder of the marketing authorisation has not made a submission to SMC regarding this product in this setting. As a result we cannot recommend its use within NHSScotland.

To read more Press Release articles, click here.